default author photo

Razelle Kurzrock

Medical College of Wisconsin

8701 Watertown Plank Road

Milwaukee, WI 53226

United States

  • Medical College of Wisconsin

SCHOLARLY PAPERS

3

DOWNLOADS

239

TOTAL CITATIONS

1

Scholarly Papers (3)

Actions:
Email selected abstracts
1.

Nectin-4 Expression Patterns and Therapeutics in Oncology

Number of pages: 31 Posted: 11 Mar 2025
Mina Nikanjam, Judith Pérez-Granado, Mark Gramling, Bruno Larvol and Razelle Kurzrock
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Medical College of Wisconsin
Downloads 95 (720,278)

Abstract:

Loading...

nectin-4, enfortumab vedotin, antibody-drug conjugate, biomarker-driven approach

2.

Atm Or Chek2 Alterations as Potential Biomarkers of Improved Outcomes with Irinotecan: Real-World Analysis of Advanced Pancreatic Ductal Adenocarcinoma

Number of pages: 31 Posted: 06 Dec 2023
Mandana Kamgar, Maahum Mehdi, Bicky Thapa, Aniko Szabo, Gulrayz Ahmed, Aditya Shreenivas, James P. Thomas, Deepika Sriram, Douglas B. Evans, Susan Tsai, Kathleen K. Christians, Beth Erickson, William A. Hall, Hui-Zi Chen, Nikki Lytle, Thomas McFall, Navonil De Sarkar, Steve Patrick, Ben George and Razelle Kurzrock
Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Barbara Ann Karmanos Cancer Institute, Medical College of Wisconsin and Medical College of Wisconsin
Downloads 93 (725,554)
Citation 1

Abstract:

Loading...

Pancreatic Neoplasms, Ataxia Telangiectasia Mutated, ATM, Checkpoint kinase 2, CHEK2, Irinotecan, Topoisomerase I inhibitors, Biomarkers.

3.

MEK Inhibitor Therapy in Pancreatic Ductal Adenocarcinoma with KRAS G12R Mutation

Number of pages: 51 Posted: 17 Oct 2024
Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, John F. Langenheim, Rachel Burge, Mohammed Aldakkak, Ryan D. Conrady, Aniko Szabo, Sam Z. Thalji, Bradley Mayer, Justin Grahl, Brian Y. Chung, Alexandria Phan, James P. Thomas, Douglas B. Evans, Kathleen K. Christians, Beth Erickson, William A. Hall, Nikki Lytle, Ben George, Susan Tsai, Channing J. Der, Razelle Kurzrock, Thomas McFall and Sneak Peek Administrator
Medical College of Wisconsin, Medical University of South Carolina, Medical College of Wisconsin, Thomas Jefferson University, Medical University of South Carolina, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Froedtert Health Inc, Froedtert Health Inc, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Medical College of Wisconsin, Ohio State University (OSU) - Wexner Medical Center, University of North Carolina (UNC) at Chapel Hill, Medical College of Wisconsin, Medical College of Wisconsin and Independent
Downloads 51 (1,063,489)

Abstract:

Loading...

Pancreas cancer, KRAS, MEK, Trametinib, hydroxychloroquine, KRAS G12R, experimental systems biology